Abstract:Infection with cagA-positive Helicobacter pylori is the strongest risk factor for the development of gastric carcinoma. The cagA gene product CagA, which is delivered into gastric epithelial cells, specifically binds to and aberrantly activates SHP-2 oncoprotein. CagA also interacts with and inhibits partitioningdefective 1 (PAR1)/MARK kinase, which phosphorylates microtubule-associated proteins to destabilize microtubules and thereby causes epithelial polarity defects. In light of the notion that microtubules… Show more
“…Nonphosphorylated CagA associates with the epithelial tight junction scaffolding protein zonula occludens 1 (ZO-1) and the transmembrane protein junctional adhesion molecule A (JAM-A), leading to nascent but incomplete assembly of tight junctions at ectopic sites of bacterial attachment (13). Recently, CagA was shown to directly bind PAR1b/MARK2, a central regulator of cell polarity, and to inhibit its kinase activity as well as to dysregulate mitotic spindle formation, thus promoting a loss of cell polarity (see "Apical-Junctional Complexes") (179,269,320). While it is evident that non-tyrosine-phosphorylated mutant forms of CagA exert effects within gastric epithelial cells, to our knowledge, there is currently no direct evidence for nonphosphorylated CagA within the host cell.…”
SUMMARY
Helicobacter pylori is a gastric pathogen that colonizes approximately 50% of the world's population. Infection with H. pylori causes chronic inflammation and significantly increases the risk of developing duodenal and gastric ulcer disease and gastric cancer. Infection with H. pylori is the strongest known risk factor for gastric cancer, which is the second leading cause of cancer-related deaths worldwide. Once H. pylori colonizes the gastric environment, it persists for the lifetime of the host, suggesting that the host immune response is ineffective in clearing this bacterium. In this review, we discuss the host immune response and examine other host factors that increase the pathogenic potential of this bacterium, including host polymorphisms, alterations to the apical-junctional complex, and the effects of environmental factors. In addition to host effects and responses, H. pylori strains are genetically diverse. We discuss the main virulence determinants in H. pylori strains and the correlation between these and the diverse clinical outcomes following H. pylori infection. Since H. pylori inhibits the gastric epithelium of half of the world, it is crucial that we continue to gain understanding of host and microbial factors that increase the risk of developing more severe clinical outcomes.
“…Nonphosphorylated CagA associates with the epithelial tight junction scaffolding protein zonula occludens 1 (ZO-1) and the transmembrane protein junctional adhesion molecule A (JAM-A), leading to nascent but incomplete assembly of tight junctions at ectopic sites of bacterial attachment (13). Recently, CagA was shown to directly bind PAR1b/MARK2, a central regulator of cell polarity, and to inhibit its kinase activity as well as to dysregulate mitotic spindle formation, thus promoting a loss of cell polarity (see "Apical-Junctional Complexes") (179,269,320). While it is evident that non-tyrosine-phosphorylated mutant forms of CagA exert effects within gastric epithelial cells, to our knowledge, there is currently no direct evidence for nonphosphorylated CagA within the host cell.…”
SUMMARY
Helicobacter pylori is a gastric pathogen that colonizes approximately 50% of the world's population. Infection with H. pylori causes chronic inflammation and significantly increases the risk of developing duodenal and gastric ulcer disease and gastric cancer. Infection with H. pylori is the strongest known risk factor for gastric cancer, which is the second leading cause of cancer-related deaths worldwide. Once H. pylori colonizes the gastric environment, it persists for the lifetime of the host, suggesting that the host immune response is ineffective in clearing this bacterium. In this review, we discuss the host immune response and examine other host factors that increase the pathogenic potential of this bacterium, including host polymorphisms, alterations to the apical-junctional complex, and the effects of environmental factors. In addition to host effects and responses, H. pylori strains are genetically diverse. We discuss the main virulence determinants in H. pylori strains and the correlation between these and the diverse clinical outcomes following H. pylori infection. Since H. pylori inhibits the gastric epithelium of half of the world, it is crucial that we continue to gain understanding of host and microbial factors that increase the risk of developing more severe clinical outcomes.
“…It is interesting to note that although chronic gastritis appears to be associated with the development of gastric carcinoma in humans, there were no signs of gastritis or systemic in fl ammation in CagA transgenic mice, including those with gastrointestinal carcinomas. Interaction of CagA with PAR1/MARK (partitioning defective 1/ microtubule af fi nity-regulating kinase) may also contribute to the carcinogenic process because it induces chromosomal instability by destabilizing the microtubules during mitosis (Umeda et al 2009 ) .…”
Section: Helicobacter Pylori : An Inducer Of the Cpg Island Methylatomentioning
“…Indeed, mutation frequencies are more elevated in mice infected with H. pylori, with a prevalence of transversion mutations (AT to GC and GC to AT), resulting from oxidative DNA damage [14]. Umeda and co-workers showed that CagA, a virulence factor delivered into H. pylori-infected cells delays prophase and metaphase, resulting in the incorrect orientation of the mitotic spindle and an abnormal division axis, generating anomalies in chromosome segregation and genomic instability [15]. H. pylori also alters the level of the pro-apoptotic regulator p53 through the promotion of ubiquitin-dependent proteasome degradation in a CagA-dependent manner [16,17].…”
Section: Helicobacter Pylori Alters Content and Maintenance Of The Homentioning
Eukaryotic cells repair thousands of lesions arising in the genome at each cell cycle. The most hazardous damage is likely DNA doublestrand breaks (DSB) that cleave the double helix backbone. DSBs occur naturally during T-cell receptor and immunoglobulin gene recombination in lymphocytes. DSBs can also arise as a consequence of exogenous stresses (e.g. ionizing irradiation, chemotherapeutic drugs, viruses) or oxidative processes. An increasing number of studies have reported that infection with pathogenic bacteria also alters the host genome, producing DSB and other modifications on DNA. This review focuses on recent data on bacteria-induced DNA damage and the known strategies used by these pathogens to maintain a physiological niche in the host. Even after DNA repair in infected cells, "scars" often remain on chromosomes and might generate genomic instability at the next cell division. Chronic inflammation in tissue, combined with infection and DNA damage, can give rise to genomic instability and eventually cancer. A functional link between the DNA damage response and the innate immune response has been recently established. Pathogenic bacteria also highjack the host cell cycle, often acting on the stability of the master regulator p53, or dampen the DNA damage response to support bacterial replication in an appropriate reservoir. Except in a few cases, the molecular mechanisms responsible for DNA lesions are poorly understood, although ROS release during infection is a serious candidate for generating DNA breaks. Thus, chronic or repetitive infections with genotoxic bacteria represent a common source of DNA lesions that compromise host genome integrity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.